Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | PDE2A | O00408 | 1/20 | 0.42 |
| ▸ | PDE5A | O76074 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.42 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.42 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23833770 | 0.85 | AKR1C3 (0.41) | ALDH1A1PDE2APDE5ACYP3A4ALOX15 | |
| SCHEMBL2434154 | 0.81 | SMN1; SMN2 (0.62) | ALDH1A1PDE2APDE5ACYP3A4ALOX15 | |
| SCHEMBL9367150 | 0.79 | AKR1C3 (0.50) | ALDH1A1TDP1AKR1C3AKR1C2SMN1; SMN2 | |
| SCHEMBL9203312 | 0.78 | ALDH1A1 (0.55) | ALDH1A1CYP3A4TDP1AKR1C3AKR1C2 | |
| SCHEMBL25754876 | 0.78 | TBXA2R (0.50) | TDP1SMN1; SMN2TBXA2RHSD11B1L3MBTL1 | |
| SCHEMBL29435937 | 0.77 | HTT (0.58) | ALDH1A1CYP3A4BLMTDP1AKR1C3 | |
| SCHEMBL8430948 | 0.77 | HTT (0.58) | ALDH1A1CYP3A4BLMTDP1AKR1C3 | |
| SCHEMBL3550146 | 0.77 | HTT (0.58) | ALDH1A1CYP3A4BLMTDP1AKR1C3 | |
| SCHEMBL10916019 | 0.76 | CYP1A2 (0.52) | ALDH1A1PDE7ATDP1AKR1C3AKR1C2 | |
| SCHEMBL30062398 | 0.76 | HSPB1 (0.56) | ALDH1A1TDP1AKR1C3AKR1C2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | NOVO NORDISK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| EP-1183229-B1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK AS (DK) | 2005-10-26 | — | — | EP | disclosed |
| US-6953812-B2 | Glucagon antagonists/inverse agonists | NOVO NORDISK, INC. (DK) | 2005-10-11 | — | — | US | disclosed |
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2005-09-15 | — | — | US | disclosed |
| US-6875760-B2 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2005-04-05 | — | — | US | disclosed |
| US-20040024045-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2004-02-05 | — | — | US | disclosed |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2003-11-27 | — | — | US | disclosed |
| US-6562807-B2 | For prophylaxis and therapy of hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism, such as dyslipidemia, and obesity | NOVO NORDISK A/S (DK) | 2003-05-13 | — | — | US | disclosed |
| EP-1296942-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | Novo Nordisk A/S (DK) | 2003-04-02 | — | — | EP | disclosed |
| US-6503949-B1 | Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity | NORO NORDISK A/S (DK) | 2003-01-07 | — | — | US | disclosed |
| US-20020143186-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2002-10-03 | — | — | US | disclosed |
| EP-1183229-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2002-03-06 | — | — | EP | disclosed |
| WO-2002000612-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2002-01-03 | — | — | WO | disclosed |
| WO-2000069810-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | ALDH1A1 3968/4885PDE2A 404/4885PDE5A 680/4885 |
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | GLP1R, GPR119, GCGR | ALDH1A1 3968/4885PDE2A 404/4885PDE5A 680/4885 |
| US-20040024045-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | ALDH1A1 4046/4885PDE2A 478/4885PDE5A 785/4885 |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | ALDH1A1 3968/4885PDE2A 404/4885PDE5A 680/4885 |
| US-20020143186-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | ALDH1A1 4046/4885PDE2A 478/4885PDE5A 785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.